Charles Gaulin

, Associate Program Director · Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital

Credentials: · · · · · · · ·

History

Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
Present
Geisel School of Medicine
2024–Present
Geisel School of Medicine
Present

UT MD Anderson
2023–2024
Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2020–2023
Internal Medicine
Icahn School of Medicine at Mount Sinai
2016–2019
University of Sydney
2015
University of British Columbia
2011

Research

Quality of life in non-melanoma skin cancer
Review · Australasian Journal of Dermatology · 2015 · First of 3 authors · 60 citations
Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm
Review · Life · 2022 · First of 3 authors · Corresponding · 14 citations
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma
American Journal of Hematology · 2025 · 13 citations

Allison Rosenthal
2 papers
Chi Ok
2 papers
JM
Javier Munoz
2 papers
KK
Katalin Kelemen
2 papers
MT
Martin Tallman
2 papers
PJ
Preetesh Jain
2 papers
Shannon Ensign
2 papers · 1 as a fellow
Adam Kittai
1 paper
AH
Alma Habib
1 paper · 1 as a fellow
Anita Deswal
1 paper
Ashwin Kishtagari
1 paper
Ayo Falade
1 paper · 1 as a fellow

Clinical trials

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2038
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2030